Search the Newsreel

Omnicell Inc (OMCL) (Q2 2026) Earnings Call Highlights: Strong Profitability and Strategic Wins ...

Omnicell Inc. (OMCL) reported strong Q2 2026 results with revenues at the high end of guidance and EPS well above expectations, driven by favorable revenue mix and cost management. Despite this, the company revised its full-year product bookings guidance to a wide range due …

Cellectis (NASDAQ: CLLS) sets August 6 date for Q2 2026 results

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, announced it would release its second-quarter 2026 financial results on Thursday, August 6, 2026, after the close of the US market. The company specified that it would not host a conference call for these results but would …

Cellectis Q2 Results Set for Aug. 6; No Call Planned

Cellectis (CLLS) will report its second-quarter 2026 financial results on August 6, 2026, after the U.S. market closes. The company will not host a conference call to discuss these results but will make the press release available on its investor website. Investors can direct …

Cellectis to report second-quarter results after US market close

Cellectis announced it will release its second-quarter 2026 financial results on August 6, 2026, after the close of U.S. trading. The results will be posted in the investor relations press releases section of their website. This news brief was generated by Public Technologies using …

Cellectis to Report Second Quarter Financial Results on August 6, 2026

Cellectis (CLLS), a clinical-stage biotechnology company, announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, after the close of the US market. The results will be accessible via a press release on the Investors section of their website. …

Slim group (NYSE: TKC) discloses 6.4% Turkcell holding through ADS structures

The Slim family, through various entities including Grupo Financiero Inbursa and two foundations, has disclosed a collective beneficial ownership of 6.4% of Turkcell Iletisim Hizmetleri A.S. (NYSE: TKC) ordinary shares. This ownership is primarily held through American Depositary Shares (ADSs), with each ADS representing …

FuelCell Energy (NASDAQ:FCEL) rises 29% after Bloom Energy (NYSE:BE) earnings boost AI-power rally

FuelCell Energy (NASDAQ:FCEL) saw its stock jump 29% following strong earnings reported by Bloom Energy (NYSE:BE), which invigorated the AI-power sector rally. Despite this surge, FCEL's market value was still below its pre-offering benchmark due to recent share dilution, and the company continues to …

EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination

New solution may help pharmacies grow monthly vaccinations by up to 66%1 FORT WORTH, Texas, July 30, 2026--(BUSINESS WIRE)--EnlivenHealth, Inc., a subsidiary of Omnicell, Inc. ("EnlivenHealth") and a leading innovator in pharmacy technology and patient engagement solutions, today announced the launch of VaxReach, a …

Stronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)

Omnicell (OMCL) reported stronger Q2 2026 results with increased revenue and net income, alongside improved full-year 2026 revenue guidance of US$1.23 billion–US$1.25 billion. This updated outlook provides clearer insights into the company's near-term growth, potentially reshaping its investment narrative. Despite the positive guidance, investors …

AbCellera Biologics (ABCL) Is Down 5.9% After Vertex-Backed T-Cell Engager Collaboration Announcement

AbCellera Biologics (ABCL) recently announced a collaboration with Vertex Pharmaceuticals for T-cell engagers, receiving $28 million upfront and potential milestones. This deal, along with a previous one with Jazz Pharmaceuticals, validates AbCellera's technology and provides non-dilutive cash, though the company still faces risks from …

TKC|Turkcell Iletisim Hizmetleri AS|Price:5.380|Chg%:-0.040

This article provides a comprehensive stock analysis of Turkcell Iletisim Hizmetleri AS (TKC), highlighting its strong fundamentals, high growth potential, and current valuation. Despite a recent weak stock market performance, the company is recognized for its stable dividends and high institutional ownership. The analysis …

Bloom Energy Soars 28%, FuelCell Energy Rockets 27% as Q2 Results Sink In and Mizuho Upgrades

Quick Read Bloom Energy beat Q2 estimates with 165% revenue growth, and BE shares surged 26% Thursday while FuelCell Energy stock jumped 27% on the sentiment wave. Plug Power stock lagged BE and FCEL with a 9% gain and remains up 4% YTD, while …

FuelCell Energy Inc. stock rises Thursday, outperforms market

Shares of FuelCell Energy Inc. (FCEL) rose significantly on Thursday, gaining 30.64% to close at $23.62. This surge outperformed the general market, as both the NASDAQ Composite Index and the Dow Jones Industrial Average also saw gains. The stock's positive performance ended a two-day …

FuelCell Energy (NASDAQ:FCEL) Stock Price Up 18.3% - Time to Buy?

FuelCell Energy (NASDAQ:FCEL) saw its stock price surge by 18.3% to $21.39, nearing analysts' consensus target of $22.83, despite mixed analyst sentiment and weak fundamentals including a larger-than-expected quarterly loss and revenue miss. While some analysts issued "Buy" ratings, the overall consensus remains "Hold." …

Omnicell forecasts 2026 non-GAAP EPS of $2.15-$2.30 while widening product bookings range to $425M-$560M

Earnings Call Insights: Omnicell (OMCL) Q2 2026 MANAGEMENT VIEW * "We delivered solid execution in the second quarter with results at or above our expectations across key financial metrics" (Founder, Executive Chairman & CEO Randall Lipps), citing "Total revenue was $312 million" and noting …

GUIDANCE: (OMCL) Omnicell, Inc. Expects Q3 Adjusted EPS Range $0.35 - $0.43

Omnicell, Inc. (OMCL) has issued guidance for its third-quarter adjusted EPS, anticipating a range of $0.35 to $0.43. This guidance provides investors with an outlook on the company's expected financial performance for the upcoming quarter.

FuelCell Energy Shares Surge as Microsoft Earnings Highlight AI Power Demand

FuelCell Energy (FCEL) stock surged after Microsoft's strong Q4 earnings report, which highlighted increasing demand for AI infrastructure. Investors are betting that tech giants building AI data centers will seek FuelCell Energy's on-site power solutions to bypass traditional grid limitations. Despite Thursday's rebound, FCEL's …

Omnicell Announces Second Quarter 2026 Financial Results

Omnicell, Inc. reported solid financial results for the second quarter of 2026, with total revenues of $312 million, a 7% increase from the previous year. The company saw a significant improvement in GAAP net income and non-GAAP net income per diluted share, partly due …

Cellectar Biosciences to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 13

Cellectar Biosciences, Inc. will report its second quarter 2026 financial results and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time. The company, which focuses on cancer drug development using its proprietary Phospholipid Drug Conjugate™ platform, has several drug candidates …

Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance

Omnicell (NASDAQ:OMCL) reported Q2 CY2026 earnings, beating Wall Street's revenue and EPS estimates with sales up 7.4% year-on-year to $312.2 million and non-GAAP EPS of $0.94. Despite the Q2 beat and raised full-year EBITDA and EPS guidance, the stock dropped 5.6% due to weaker-than-expected …

Omnicell (OMCL) Q2 Earnings and Revenues Top Estimates

Omnicell (OMCL) reported Q2 earnings of $0.94 per share, significantly exceeding the Zacks Consensus Estimate of $0.48, and revenues of $312.21 million, also topping estimates. Despite these strong results, Omnicell shares have fallen 8.6% year-to-date, contrasting with the S&P 500's 6.9% gain. The company …

Cellebrite DI Ltd. $CLBT Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp significantly increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 107% in the first quarter, now holding 1.33 million shares valued at $18.4 million. Despite company insiders selling shares worth $2.48 million, analysts maintain a positive outlook with …

Why is Omnicell stock rallying today?

Omnicell stock initially surged after reporting strong Q2 2026 earnings, significantly beating analyst estimates for both EPS and revenue. However, the rally was short-lived as the company's Q3 and full-year guidance fell below market expectations, leading to a subsequent pullback and erasing most of …

Earnings Flash (OMCL) Omnicell, Inc. Posts Q2 Adjusted EPS $0.94 per Share, vs. FactSet Est of $0.47

Omnicell, Inc. (OMCL) announced its Q2 adjusted earnings per share (EPS) of $0.94, significantly surpassing the FactSet estimate of $0.47. The company's Q2 revenue also exceeded expectations, reporting $312.2 million against an estimated $310.2 million. Omnicell further provided a Q3 revenue outlook ranging from …

Omnicell (NASDAQ: OMCL) Q2 profit jumps as 2026 guidance raised

Omnicell (NASDAQ: OMCL) reported strong second-quarter 2026 results, with total revenues up 7% to $312 million and GAAP net income increasing to $24 million. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP EPS guidance and tightened its revenue outlook. The positive results …

Abcellera Biologics Inc (ABCL) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Abcellera Biologics Inc (ABCL), ranking it 232 out of 384 in the Biotechnology & Medical Research industry with a financial score of 6.64. The company's financial status is weak with low operating efficiency, despite a significant year-over-year …

Cellectis SA (CLLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cellectis SA (CLLS), detailing its price momentum score of 4.63 and noting its current trading range between a resistance level of $3.30 and a support level of $2.50. It presents a summary of various technical indicators like …

Millicom International Cellular (TIGO) Expected to Post Quarterly Earnings on Thursday

Millicom International Cellular (NASDAQ:TIGO) is expected to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting earnings of $0.71 per share and revenue of $2.1345 billion. The company last reported strong Q1 earnings, beating consensus estimates. Insider trading …

ABCL|Abcellera Biologics Inc|Price:5.715|Chg%:+0.025

This article provides a comprehensive stock analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's proprietary scoring system. ABCL's fundamentals are described as stable with high growth potential, and its valuation is considered fair within the Biotechnology & Medical Research industry. The report highlights …

CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 32% - Weak Earnings Momentum

Stempoint Capital LP Purchases New Shares in Celldex Therapeutics, Inc. $CLDX

Omnicell Q2 2026 Revenue Rises 7 Percent to $312 Million

Lineage Cell Therapeutics’ Aug. 6 call includes a business update

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Turkcell Iletisim Hizmetleri AS (NYSE:TKC) Reaches New 1-Year Low - Here's Why

Omnicell, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:OMCL) 2026-07-30